Biocon Q1FY27 Total Income ₹4,391 Cr, Up 9%; Net Profit ₹141 Cr

Biocon Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. Total income rose 9% year-on-year to ₹4,391 crore, while EBITDA stood at ₹902 crore with a 21% margin. Net profit after exceptional items was ₹141 crore, a significant increase from ₹31 crore in the prior year quarter. The Biopharma segment showed strong growth, with revenue up 17% year-on-year, driven by biosimilar and generic product launches. Biosimilars revenue grew 16% to ₹2,855 crore, and Generics revenue increased 21% to ₹760 crore. Services revenue saw a 16% decrease to ₹736 crore. The company highlighted strategic investments, favorable policy for biosimilars, expanded manufacturing capabilities, and successful product launches in key markets like the U.S. Interest costs were reduced by 23% due to balance sheet strengthening measures.